
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Immunoprecise Antibodies Ltd (IPA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: IPA (4-star) is a SELL. SELL since 1 days. Profits (415.22%). Updated daily EoD!
1 Year Target Price $4
1 Year Target Price $4
0 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 319.81% | Avg. Invested days 43 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 114.92M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 0.55 | 52 Weeks Range 0.27 - 3.25 | Updated Date 08/30/2025 |
52 Weeks Range 0.27 - 3.25 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -123.3% | Operating Margin (TTM) -21.11% |
Management Effectiveness
Return on Assets (TTM) -14.81% | Return on Equity (TTM) -101.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 111371814 | Price to Sales(TTM) 4.69 |
Enterprise Value 111371814 | Price to Sales(TTM) 4.69 | ||
Enterprise Value to Revenue 6.26 | Enterprise Value to EBITDA -4.68 | Shares Outstanding 46154100 | Shares Floating 41946709 |
Shares Outstanding 46154100 | Shares Floating 41946709 | ||
Percent Insiders 9.07 | Percent Institutions 8.67 |
Upturn AI SWOT
Immunoprecise Antibodies Ltd

Company Overview
History and Background
Immunoprecise Antibodies Ltd. is a biopharmaceutical company focused on therapeutic antibody discovery and development. Founded in 1989, it has evolved from a contract research organization (CRO) to an integrated discovery platform offering services and technologies across the antibody discovery value chain.
Core Business Areas
- Therapeutic Antibody Discovery: Offers a range of services for the discovery of monoclonal and bispecific antibodies, including hybridoma technology, B cell screening, and phage display. Services extend from antigen design to antibody sequencing and characterization.
- Recombinant Antibody Production: Provides recombinant antibody production services, including antibody engineering, optimization, and scale-up production.
- Contract Research Services: Offers in vitro and in vivo research services for preclinical antibody development, including preclinical testing.
Leadership and Structure
Dr. Jennifer Bath serves as President and CEO. The company has a board of directors and operates with distinct functional teams focused on research, operations, and commercial activities.
Top Products and Market Share
Key Offerings
- Antibody Discovery Services: Comprehensive antibody discovery platform offering various technologies. Market share data is not precisely defined due to the fragmented nature of the CRO market, but the company competes with larger CROs and specialized antibody discovery firms. Competitors: Charles River Laboratories, WuXi AppTec, GenScript Biotech.
- Custom Antibody Production: Custom antibody production from milligram to gram scale. Competes with other CROs, typically serving smaller pharmaceutical and biotechnology firms. Competitors: Thermo Fisher Scientific, Abcam.
- Preclinical Research Services: Offers preclinical in vivo and in vitro research services. Competes with other preclinical CROs. Competitors: Covance, Charles River Laboratories.
Market Dynamics
Industry Overview
The biopharmaceutical industry, and especially the antibody therapeutics segment, is experiencing substantial growth driven by advances in immunotherapy, targeted therapies, and diagnostics. The CRO market is also expanding, driven by the increasing R&D spending in the pharmaceutical sector and the need for specialized expertise.
Positioning
Immunoprecise Antibodies Ltd. positions itself as a full-service antibody discovery and development company, providing integrated solutions from target identification to preclinical development. Its competitive advantages include its diverse technology platform and its focus on complex targets.
Total Addressable Market (TAM)
The global antibody therapeutics market is estimated to reach hundreds of billions of dollars. The global CRO market is in the tens of billions. Immunoprecise Antibodies Ltd. targets a segment of this market, focusing on early-stage antibody discovery and preclinical services.
Upturn SWOT Analysis
Strengths
- Comprehensive antibody discovery platform
- Expertise in complex targets
- Integrated service offerings
- Experienced leadership team
Weaknesses
- Relatively small size compared to major CROs
- Limited marketing resources
- Dependence on research funding trends
- Limited late-stage clinical development capabilities
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships with larger pharmaceutical companies
- Increased demand for antibody therapeutics
- Leveraging AI and machine learning for antibody discovery
Threats
- Competition from larger CROs
- Patent disputes
- Changes in regulatory landscape
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- Charles River Laboratories (CRL)
- WuXi AppTec (WXUSF)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
Immunoprecise Antibodies Ltd. is significantly smaller than its main competitors, such as Charles River Laboratories and WuXi AppTec. It competes by offering specialized expertise and integrated solutions, targeting niche markets and smaller pharmaceutical companies.
Major Acquisitions
BioStrand BV
- Year: 2022
- Acquisition Price (USD millions): 14.5
- Strategic Rationale: Accelerated discovery of novel antibody therapeutics, expands IP portfolio, increases competitiveness.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on financial data which is not available.
Future Projections: Future projections depend on analyst estimates, which can vary based on market conditions and company performance. Analyst estimates depend on financial data which is not available.
Recent Initiatives: Expanding its technology platform through acquisitions and strategic alliances and focusing on high-growth areas like multi-specific antibody therapies.
Summary
Immunoprecise Antibodies Ltd. is a biopharmaceutical company that specializes in antibody discovery and development. It offers a comprehensive service portfolio and has made strategic acquisitions to expand its capabilities. While smaller than its major competitors, it serves the needs of small to medium pharmaceutical companies. Moving forward, it should focus on expanding sales, marketing, and production efficiency.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Reports
- Public Filings
Disclaimers:
This analysis is based on publicly available information and represents a general overview of Immunoprecise Antibodies Ltd. Financial data is estimated or based on industry averages due to availability constraints.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Immunoprecise Antibodies Ltd
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2017-01-03 | CEO, President & Non-Independent Director Dr. Jennifer Lynne Bath Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.ipatherapeutics.com |
Full time employees 81 | Website https://www.ipatherapeutics.com |
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in Austin, Texas.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.